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INTRODUCTION
The objective of this project was to develop and evaluate fluorine-18 labeled fluorocholine (18F-fluorocholine) as an imaging agent for positron emission tomography (PET) detection of malignancy in anatomical sextants of the prostate gland. The rationale for evaluating fluorocholine as an oncologic tracer applicable to prostate cancer is based on observations of increased choline and fluorocholine metabolism in malignant prostate tissue relative to normal tissue. Information about tumor activity, location, and volume obtained with PET may have significant clinical value in refining diagnostic and therapeutic approaches against primary prostate cancer.
REPORT SUMMARY
This final addendum report describes the work performed during a no-cost extension period from dates 20 December 2008 to 19 December 2009 . Immunohistochemical analysis of prostate tumors using the MIB-1 (Ki-67) immunohistochemical stain was completed at the Armed Forces Institute of Pathology (AFIP) in March 2009. These results were compared to images of the prostate that were obtained pre-operatively using 18F-fluorocholine PET or PET/CT. Appendix 2 contains an abstract summarizing the findings of this radiopathologic correlation study. The completion of this study constitutes the fulfillment of all tasks listed in the project Statement of Work (SOW). Expenditures related to the completion of a radiopathologic correlation study during the current period are summarized below:
Item
Budgeted Actual Table: Expenses for the current no-cost extension period BODY Prostate cancer remains the second leading cause of male cancer death in the United States. If treated at an organ-confined stage, the expected 5-year survival from prostate cancer is 100% as compared to a 33% 5-year survival for metastatic prostate cancer (1) . In vivo imaging capable of localizing prostate cancer may increase the rate of early detection and improve pretreatment risk stratification and treatment decision-making. The goal of this study was to evaluate the potential diagnostic and prognostic value of 18F-fluorocholine PET and PET/CT imaging as a method for imaging primary prostate cancer.
Items Relevant to SOW Task 1: Study Preparation
This task was completed as described in the previous year's Addendum Report.
Items Relevant to SOW Tasks 2: Subject Recruitment and Data Collection
This project was an IRB-approved clinical research study that enrolled 25 human subjects. Subject recruitment has been completed in the previous year and the study has been officially closed to further accrual since 9 June 2008. A human subjects study completion letter was submitted to the Human Research Protection Office (HRPO) on 7 October 2009. Records indicate there were no adverse events, unanticipated problems involving risks to subjects or others, withdrawal of subjects from research, or complaints about the research during the lifetime of the project.
Task 2d was completed in March 2009. Task 2d consisted of immunohistochemical analysis of prostate specimens for expression of the Ki-67 antigen. This work was completed under the Ki-67 analysis has previously been shown to have potential prognostic value as a marker of tumor proliferation in clinically localized prostate cancer (7) . A hypothesized correlation between tumor 18F-choline uptake and expression of Ki-67 would lend support for the potential prognostic value of 18F-fluorocholine PET/CT as a prostate imaging modality. Appendix 2 contains a scientific abstract which summarizes the results of the radiohistopathologic correlation study comparing the immunohistochemical findings with 18F-fluorocholine PET/CT. Data from 24 of the 25 subjects was available for this correlation study due to a computer malfunction at TAMC that resulted in the loss of PET/CT data from one subject. Although higher 18F-choline uptake was an indicator of malignant prostate tumors (as we previously reported), no statistically significant correlation between prostate tumor Ki-67 labeling and prostatic 18F-fluorocholine uptake was observed. This finding supports the possibility that tumor uptake on 18F-fluorocholine PET/CT may be reflective of other characteristics of malignancy besides proliferative activity. The abstract will be submitted for presentation at a scientific meeting in 2010 (conference TBD).
Items Relevant to SOW Task 3: Data Analyses
The completion of this task was described in the previous year's Addendum Report.
Items Relevant SOW Task 4: Reporting and Design of Secondary Studies
A grant proposal to investigate 18F-fluorocholine PET/CT for monitoring therapeutic response to chemotherapy and hormone therapy in advanced metastatic prostate cancer received funding from the National Cancer Institute in June 2009 (NIH R21CA139687, PI-Kwee). Imaging protocols developed during the current study are being used in the two clinical imaging trials supported by this grant. These trials are evaluating 18F-fluorocholine PET/CT for whole-body monitoring of therapeutic response in advanced prostate cancer. Appendix 3 contains summaries of these clinical studies along with a peer-reviewed publication that summarizes the pilot data for this project and its imaging protocols.
In addition, a collaborative study between The Queen's Medical Center and Phillips Research (Phillips Medical Systems, N.A.) has been initiated to study prostatic 18F-fluorocholine kinetic analysis as a potential means to further improve the sextant localization of primary prostate cancer. The rationale for this study is based on observations of rapid kinetic uptake of 18F-fluorocholine by the prostate tumors observed in the current study. This parametric analysis of 18F-fluorocholine PET/CT data was summarized in the previous year's Addendum Report (Appendix 2, Reference 5, from 2008 Addendum Report).
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Final Addendum Report PI-Kwee, Sandi A. a. Begin subject recruitment at TAMC and QMC. A total of 25 subjects will be recruited from both sites over a 16 month period.
b. Subjects will undergo whole-body F-18 FCH PET or PET/CT scanning to acquire images of the prostate gland.
c. Subjects not undergoing PET/CT will undergo a separate CT at QMC. d. Following surgery, the prostatectomy specimens will delivered to AFIP for processing and analysis. Analysis procedures include surgical histopathology and immunohistochemical staining for the Ki-67 antigen. The data will be recorded on study-specific pathology forms. e. All data will be entered into a study database for analysis. Purpose: Immunohistochemical Ki-67 labeling (MIB-1 index) has been shown to have potential prognostic value in clinically localized prostate cancer. To determine whether 18F-choline PET/CT can provide a prognostic measure of tumor proliferation in primary prostate cancer, we compared the immunohistochemical MIB-1 labeling index to tumor 18F-choline uptake corresponding to malignantly involved prostate sextants as determined through step-section analysis of the prostate following radical prostatectomy. Materials and Methods: Histopathologic analysis was performed on completely embedded whole-mounted prostate specimens from 24 subjects who received preoperative prostate 18F-choline PET or PET/CT imaging. The PET images were acquired 10 minutes following intravenous administration of 3.3 to 4 MBq/kg of 18F-choline. The images were analyzed by region of interest analysis to obtain the maximum standardized uptake value (SUVmax) corresponding to prostate sextants. Diagnostic accuracy was estimated by receiver operator characteristic (ROC) analysis. Discrete tumors measuring at least 5mm in diameter were identified for assessment of the MIB-1 labeling index. The evaluation for Ki-67 antigen expression was performed by antigen retrieval and immunohistochemical labeling with the monoclonal antibody MIB-1. A labeling index for each malignantly involved sextant was expressed as the percentage of tumor cells demonstrating nuclear staining in each section. Regression analysis was performed to assess the correlation between immunohistochemical labeling index and SUVmax in the most active prostate sextant for each tumor. Results: The average weight of the prostate specimens was 46 grams (s.d. 23 grams). The average total tumor volume was 8.2 cc (s.d. 9 cc). Two patients who received hormonal therapy acutely prior to surgery were excluded from ROC analysis since the PET/CT images from both patients demonstrated globally diminished prostatic activity. Treatment effects were also evident on histopathologic analysis of the prostate specimens from these patients. The computed area under the ROC curve (AUC) was 0.80 (sensitivity 82% if specificity 60%). Thirty-four macroscopic and discrete tumors (1 to 3 per specimen) were available for Ki-67 analysis. The correlation between MIB-1 labeling index and sextant SUVmax in malignant sextants was not statistically significant (r=0.12, p=0.5). No significant correlation between Gleason sum score and SUVmax was observed. Discussion: Acute administration of hormonal therapy may result in diminished prostatic 18F-choline uptake on PET/CT. This observation suggests that 18F-fluorocholine PET/CT may have value as a means of measuring therapeutic response in prostate cancer. The lack of a significant correlation between tumor Ki-67 expression and 18F-fluorocholine uptake in primary prostate cancer suggests that 18F-fluorocholine uptake may not strongly reflect tumor cell proliferation in the prostate gland. Increased 18F-fluorocholine uptake by malignant prostate tumors may relate to a characteristic other than increased proliferative activity in malignancy.
Final Addendum Report PI-Kwee, Sandi A. Abstract Purpose Apply measurability criteria based on the response evaluation criteria in solid tumors (RECIST) to lesions found on 18 F-choline positron emission tomography (PET)/computerized tomography (CT) in patients with hormone refractory prostate cancer. Methods Whole-body PET followed by CT or in-line PET/CT using 3.3-4 MBq/kg of 18 F-choline was performed prospectively on 30 patients with prostate cancer, castrate testosterone levels, and rising post-treatment prostate specific antigen (PSA) levels. Lesions demonstrating increased 18 F-choline uptake were classified as measurable or non-measureable based on RECIST. Results Three patients were known previously to have RECIST measurable lesions, 10 patients had metastatic findings on radionuclide bone scan, and 17 patients had elevated serum PSA level as the only evidence of disease. Lesions demonstrating increased 18 F-choline uptake were found in 28 (93%) patients. Thirty-eight PET/CT lesions from 14 patients were measurable by RECIST. Lymph node maximum standardized uptake value (SUV max ) correlated with lymph node diameter (Pearson r = 0.44, p \ 0. 001). RECIST measurable lymph node SUV max was significantly higher than that of non-measurable nodes (8.1 vs. 3.7, p \ 0.0001). Detection of skeletal, prostatic, or RECIST-compatible lesions was more likely with a PSA level greater than 4.0 ng/ml (Fisher exact p = 0.0005). Conclusion Lesions detected with 18 F-choline PET/CT are frequently measurable by RECIST at baseline. Therefore, it may be feasible to include comparisons to RECIST in evaluations of 18 F-choline as a therapeutic response marker for hormone refractory prostate cancer.
Keywords Positron emission tomography Á Fluorocholine Á Prostate carcinoma Introduction Chemotherapy has traditionally been considered ineffective at prolonging the survival of patients with hormone refractory prostate cancer (HRPC). However, two large clinical trials (TAX 327 and Southwest Oncology Group 99-16) recently demonstrated improved survival in patients with progressive HRPC treated with docetaxel-based chemotherapy [1, 2] . Although these studies rekindled a role for chemotherapy in progressive HRPC, the survival benefits reported in these studies were modest, on the order of 2-3 months. Therefore, there is continuing interest in new chemotherapeutic agents or agents which can be combined with docetaxel to further enhance survival in HRPC.
Unfortunately, the task of quantifying disease progression in patients with HRPC is difficult and continues to hinder the progress of clinical trials [3, 4] . Morphologic criteria such as the response evaluation criteria in solid tumors (RECIST), used in cancer trials to measure tumor response, have proven difficult to apply to prostate cancer The findings and conclusions expressed in this study do not necessarily represent the views of The Queen's Medical Center. [3, 5] . Not only is the prostate excluded as a measurable disease site by RECIST, but also the skeletal system which often dictates morbidity and mortality in HRPC is also largely ignored by these criteria. While soft-tissue metastases are considered measurable by standard imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI), such lesions may be difficult to find in many patients with advanced prostate cancer. In one study, conventional radiographic workup yielded RECIST measurable lesions in only 43 and 16% of patients with castrate and non-castrate metastatic prostate cancer [3] . Consequently, many patients with HRPC could be excluded from clinical trials if RECIST were used exclusively to define study endpoints or eligibility.
Choline is essential for the synthesis of cell membrane phospholipids. Observations of upregulated choline metabolism and increased choline kinase expression in cancer have fueled interest in radiolabeled choline derivatives as oncologic tracers for positron emission tomography (PET) [6, 7] . This approach has shown feasibility in prostate cancer using the tracer fluorine-18 fluoromethylcholine ( 18 F-choline) [8] [9] [10] [11] . As a preliminary step in evaluating 18 F-choline PET/CT as a method for measuring prostate cancer tumor response, we assessed the frequency of RECIST compatible lesions identified on 18 F-choline PET/CT in patients with HRPC.
Method

Subjects
The study was approved by our institutional review board. All patients provided written informed consent. Thirty consecutive patients were enrolled prospectively. The criteria for enrollment was a diagnosis of HRPC based on a rising serum prostate specific antigen (PSA) level with castrate levels of testosterone while on anti-androgen therapy. Furthermore, the rise in PSA was documented on three occasions more than 1 week apart, with a total rise of more than 50% from baseline at enrollment. PET imaging PET was performed on patients 1-12 using a Hamamatsu SHR-22000 PET scanning instrument (Hamamatsu Photonics, Hamamatsu-City, Japan) with spatial resolution near the field of view center of 3.5 mm transaxially and 4.2 mm axially. Transmission scans of the body in the supine position were acquired using two Germanium-68 rod sources over 4 or 5 fields of view starting from the pelvis. Transmission scans at each field lasted 3 min. Ten minutes after intravenous injection of 3.3-4 MBq/kg of 18 F-choline, corresponding emission scans in 2D-mode were acquired at 7 min per field of view. Image reconstruction employed an ordered subsets expectation maximization algorithm. Segmented attenuation correction was based on the measured transmission data. A subsequent non-contrast CT of the abdomen or pelvis was performed within 7 days if abnormal 18 F-choline uptake was noted on PET. CT was performed using a 4-channel multi-detector CT scanner (Picker MX 8000; Marconi Medical Systems, Cleveland, OH) with the following parameters: 120 kV, 200 mA/slice, rotation time 0.5 s, slice thickness/interval 3.0 mm.
PET/CT was performed on patients 13-30 using a Philips Gemini TF-64 PET/CT scanner (Philips Medical Systems, N.A., Bothell, WA) with spatial resolution near the field of view center of 4.8 mm in transverse and axial directions [13] . A CT transmission scan in the supine position was acquired from the pelvis to the skull. The 64-channel helical CT scanning parameters were: 120 kVp, 50 mA/slice, rotation time 0.75 s, slice thickness/interval 5.0 mm. No intravenous contrast was used with CT. At 10 min after intravenous injection of 3.3-4 MBq/kg of 18 F-choline, emission scans were acquired from mid-thigh to skull over 8-11 bed positions at 2 min per position. Image reconstruction employed a list-mode version of a maximum likelihood expectation maximization algorithm with a time-of-flight kernel applied in both the forwardand back-projection operations. CT data were used for attenuation correction.
Image analysis
Visual image analysis was performed by two readers with blinding to clinical data at the time of interpretation (S.K., M.C.). PET images were assessed visually for areas of increased 18 F-choline uptake as determined by reader consensus. Both readers have experience in interpreting 18 F-choline uptake in primary and metastatic prostate cancer [14, 15] . Images acquired from 10 healthy male control subjects using the Gemini TF-64 PET/CT and images acquired from 10 men with primary brain tumors and no other known malignancies using the Hamamatsu SHR-22000 were used as references for normal 18 F-choline biodistribution. None of these reference scans demonstrated extracranial uptake that could be classified as a lesion by the study criteria.
PET and CT images were spatially registered and reviewed on a workstation (Hermes, Hermes Medical Solutions, Battle Ground, WA). PET and CT could be viewed separately or alpha-blended in a single image. Region of interest (ROI) analyses and morphometry were performed on separate PET and CT windows. Lesions demonstrating increased 18 F-choline uptake were anatomically categorized as a skeletal lesion, prostate lesion, or tissue lesion. Increased uptake was defined as visually discernable activity above normal tissue activity or background activity in the case of lymph nodes. For this study, inguinal lymph nodes were not classified because benign inguinal nodes can transiently demonstrate increased 18 F-choline uptake [10] .
The maximum standardized uptake value (SUV max ) of each lesion was measured by ROI analysis. Standardized uptake value is defined as measured voxel activity divided by injected radioactivity normalized to body weight. Because 18 F-choline is not re-absorbed by the kidneys (Fig. 1) , focal activity along the ureteral tract was not considered to be a potential lesion to avoid the possibility of misclassifying excreted activity as a lesion.
Lesions exhibiting increased 18 F-choline uptake were classified as measureable or non-measureable based on published guidelines on RECIST [5] . As recommended by RECIST, prostate and skeletal lesions were deemed nonmeasureable. The longest diameter of all tissue lesions was measured on the CT images. Because helical CT was used, a diameter of 10 mm or greater defined a measurable lesion. Lymph nodes clusters were considered a single lesion if their delineation could not be made on the basis of CT.
Radionuclide bone scan findings were compared with the skeletal findings on PET/CT. Bone scans performed within the past 12 weeks were classified according to their clinical reports as positive or negative for skeletal metastases. In patients with positive bone scans, results were further classified as demonstrating ''new lesions'' or ''no new lesions'' based on Prostate Cancer Working Group 2 recommendations for bone scan interpretation [16] .
Statistical analysis
Differences in sample means were tested for significance using Student's t test. Dichotomous associations were assessed by Fisher's exact test using two-sided p values. Correlation was measured using the Pearson product moment coefficient. A p value of less than 0.05 was considered significant. Statistical analysis was performed using SAS Version 9 (SAS Institute Inc., Cary, NC). Because imaging studies were not compared to histopathologic reference data, sensitivity and specificity were not estimated.
Results
The mean age was 70 years (range 58-86 years). The mean and median PSA level was 175 and 12 ng/ml at enrollment (range 0.9-3383 ng/ml). Three patients were known to have RECIST measurable lesions (Table 1: patients 11, 18 , and 25), 9 patients had new metastatic findings on radionuclide bone scan, 1 patient had previous metastatic findings on bone scan that were decreasing in intensity on the most recent scan, and 17 patients had elevated serum PSA level as the only evidence of disease. Lesions demonstrating increased 18 F-choline uptake were identified in 28 (93%) out of 30 patients. All 24 patients with PSA levels of greater than 4.0 ng/ml demonstrated increased 18 F-choline uptake in either the skeletal system, the prostate gland, or a RECIST compatible lesion. Twelve of these patients had at least one measurable lymph node on PET/CT. The association between PSA greater than 4.0 ng/ml and increased 18 F-choline uptake in a skeletal, prostatic, or RECISTcompatible lesion was significant (Fisher exact p = 0.0005). Increased 18 F-choline uptake limited to non-measurable lesions of the skeleton, prostate, or a combination of nonmeasurable lesions were noted in 5, 4, and 3 patients, respectively. Of 6 patients with a PSA level of less than 4.0 ng/ml, 2 exhibited no areas of increased 18 F-choline uptake, 3 showed uptake limited to non-measurable lesions, and 1 showed increased 18 F-choline uptake corresponding to a measurable lesion (a single 10 mm lymph node).
Tissue lesions
Focal uptake in the prostate gland was observed in 10 (33%) out of 30 patients. Four of these patients had RE-CIST measurable lesions in other areas. A total of 55 nonprostate tissue lesions were identified in 18 (60%) patients on the basis of increased 18 F-choline uptake (example shown in Fig. 1 ). These extraprostatic lesions corresponded to 54 lymph nodes and 1 adrenal mass, all also evident on CT alone. Of these, 38 (69%) lesions from 14 (47%) patients measured 10 mm or greater in diameter and were classified as measureable lesions, including the adrenal mass which was confirmed by biopsy to be a metastasis (Fig. 2) . The mean SUV max of RECIST measurable lymph nodes was significantly greater than in RECIST non-measurable lymph nodes (8.1 vs. 3.7, p \ 0.0001). Because the results could be skewed by a disproportionate number of lymph nodes in one patient, differences in SUV max were also tested for significance excluding the data from patient 11. Following this exclusion, the mean SUV max of RECIST measurable lymph nodes remained significantly greater than that of RECIST non-measurable lymph nodes (5.8 vs. 2.9, p \ 0.001). The correlation between lymph node diameter and lymph node SUV max was statistically significant (Pearson r = 0.44, p \ 0. 05 including patient 11; Pearson r = 0.51, p \ 0.05 excluding patient 11; Fig. 3 ).
Skeletal lesions
Bone scans performed within 3 months of the study were available from 24 patients. The mean time interval between bone scan and PET was 18 days (range 1-72 days). In 14 (58%) of these patients, bone scans showed no evidence of skeletal metastasis. In 13 of the 14 patients, PET demonstrated no focal increases in skeletal activity. In one patient (subject 9), increased lumbar vertebral activity was noted on 18 F-choline PET although the corresponding bone scan was negative. Clinical and radiographic evidence of skeletal metastatic progression, particularly in the lumbar spine, appeared within 12 months indicating a true-positive finding on the original PET scan (Fig. 4) .
In 9 patients, new lesions were identified on the most recent bone scan as compared to a previous scan. PET demonstrated foci of increased skeletal uptake in all 9 patients. In one patient (subject 21), the most recent bone scan was positive for skeletal metastases, but showed fewer lesions than the previous scan, suggesting treatment-related regression of skeletal metastases. No increases in skeletal 18 F-choline uptake were observed in this patient.
Discussion
A consensus committee of clinical investigators recently adopted a clinical states model of prostate cancer to facilitate trial design and patient management [16] . This model provides a working framework for measuring and reporting outcomes based on disease manifestation, taking into account well-known problems in disease assessment under certain clinical situations. The committee revised criteria for authenticating disease progression using existing imaging techniques without precluding the future adoption of advanced imaging techniques such as PET/CT or MRI. The criteria incorporate RECIST, although additional criteria were included partly to overcome the limitations of RECIST in prostate cancer. Because the evaluation of molecular imaging in clinical trials would benefit from comparisons against conventional methods, we sought to determine the feasibility of evaluating tumor responses to chemotherapy with 18 F-choline PET/CT by Tissue lesions measurable by RECIST were found in 47% of study patients. This percentage of patients with measurable disease is not significantly higher than reported in other studies, possibly because lymph node pre-dominant disease is less common than skeletal metastatic disease [3] . Taking skeletal and prostate lesions into account, abnormal findings were identified in 93% of the patients in this study. This could imply that a significant amount of disease may be overlooked by prostate cancer clinical trials that rely heavily on RECIST as a surrogate marker of response.
There are a number of studies that have preliminarily evaluated 18 F-choline PET/CT for clinical staging of prostate cancer. In high-risk patients with clinically localized prostate cancer (pre-prostatectomy, PSA [ 10 ng/ml, Gleason sum [ 7, non-castrate), Hacker et al. [17] reported that 18 F-choline PET/CT was less sensitive than extended pelvic lymph node dissection or sentinel pelvic lymph node dissection for detecting pelvic lymph node metastases. This is not surprising given that most lesions would likely fall below the spatial resolution of PET/CT at this early stage [18] . At more advanced stages of disease, Price et al. [10] demonstrated greater feasibility for detecting primary and metastatic prostate cancer, with significantly more lesions detected on 18 F-choline PET as compared to conventional 18 F-fluorodeoxyglucose (FDG) PET in both castrate and non-castrate prostate cancer. Cimitan et al. reported that in patients who have previously undergone treatment, skeletal or visceral metastases were more likely to be detected by 18 F-choline PET/CT if the PSA level was greater than 4.0 ng/ml [19] . In contrast, Heinisch et al. [8] found that 18 F-choline PET/CT could consistently yield true positive results at PSA levels of less than 5.0 ng/ml, although this study included mostly patients who have had radical prostatectomy. Feasibility for detecting localized recurrence following radical prostatectomy with PSA levels of less than 1.0 ng/ml was also reported in a study by Vees et al. [20] . In the current study, lesions were more likely to be detected at a PSA of greater than 4.0 ng/ml, although it was still possible to detect smaller non-measurable lesions at PSA levels below 4.0 ng/ml. Unlike these other studies, the current study was not intended to evaluate 18 F-choline PET/CT as a staging tool because most patients with metastatic cancer are unlikely to benefit from non-systemic treatment of their disease. Rather, the aim of this study was to assess feasibility for identifying target lesions for monitoring, because the ability to accurately monitor lesions during therapy could ultimately hasten the discovery of new systemic agents for enhancing survival in HRPC.
In this study, the skeletal findings on 18 F-choline PET/ CT corresponded well to radionuclide bone scan findings. Although RECIST omits skeletal lesions, the ability of 18 F-choline PET/CT to localize skeletal lesions raises the possibility of morphometric or metabolic assessment of bone metastases by other criteria. There have already been attempts to adopt RECIST to skeletal lesions imaged by MRI [21] . Because whole-body MRI has not yet become practical, whole-body 18 F-choline PET/CT may help to direct MRI toward measurable lesions. An observation in this study that treated bone metastases can have decreasing but persistent activity on serial radionuclide bone scans without significant uptake of 18 F-choline raises the possibility that 18 F-choline PET/CT is more specific than bone scans for post-treatment monitoring of skeletal disease. Additional studies evaluating 18 F-choline PET/CT as a means of gauging skeletal tumor response are needed to further test this possibility. Conventional PET imaging with 18 F-FDG has also been studied as a means of monitoring disease progression in HRPC. While this technique is generally considered to have low sensitivity for prostate cancer [22] [23] [24] , it may have some value for gauging responses to systemic therapies in advanced prostate cancer [25, 26] . In a study by Morris et al., the appearance of new lesions on 18 F-FDG PET, or a 33% or greater increase in the SUV max of an existing lesion, could reliably distinguished progressors from non-progressors after docetaxel-based chemotherapy [26] . It would be of interest to include comparisons with 18 F-FDG PET/CT in future evaluations of 18 F-choline PET/ CT for HRPC.
The limitations of this study are worth noting. Most importantly, the majority of lesions in this study were not biopsied. Without a histologic standard of reference, the diagnostic sensitivity and specificity of 18 F-choline PET/ CT could not be estimated accurately. Because of the preliminary nature of this study, it was impractical to pursue routine biopsy due to issues of morbidity, sampling error, and the lack of specificity for many conventional imaging results. Although histopathologic confirmation is not mandated by RECIST, the application of 18 F-choline PET as a tumor response measure should await further histopathological validation. The results of this study merely support the feasibility of applying RECIST to aid in the evaluation of 18 F-choline PET/CT as a response marker. Further studies in a greater number patients with varying PSA levels would be required to accurately evaluate lesion detection at different PSA levels, as well as to determine whether 18 F-choline PET/CT can complement PSA for measuring tumor burden and response. Subsequent studies would also benefit by including correlations with clinical outcomes, because better tools for risk-stratification are needed for prostate cancer.
Conclusion
Tumor response measures in clinical trials continue to evolve as molecular imaging techniques gain increasing acceptance in clinical oncology. However, the replacement of morphometric measures with molecular markers as measures of disease progression should proceed cautiously through the validation of molecular imaging techniques by existing criteria and clinical outcome. Comparisons with RECIST appear feasible for evaluations of 18 F-choline PET/CT as a therapeutic response marker. The clinical relevance of prostatic and skeletal lesions detected by 18 F-PET/CT is also worth investigating, because these potentially significant manifestations of disease are not taken into account by conventional RECIST. 
